2nd Quarter - Report

AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. for AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC

Firm
Client
Income
—
Expenses
$910,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues respecting the medical expense deduction.

LobbyistCovered position, as disclosed
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —

Contacted: Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Food & Drug Administration (FDA); Environmental Protection Agency (EPA); Energy, Dept of; Centers For Disease Control & Prevention (CDC); White House Office; Veterans Affairs, Dept of (VA); U.S. Agency for International Development (USAID); SENATE; HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL); Health & Human Services, Dept of (HHS)

Health Issues HCR

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including: HR 1010, to provide that the short-term rule has no force or effect; HR 986 & S 466, Protecting Americans with Pre-Existing Conditions Act; HR 1425, State Health Care Premium Reduction Act; HR 1386, Expand Navigators Resources for Outreach, Learning, and Longevity Act of 2019; HR 1884, Protecting Pre-Existing Conditions & Making Health Care More Affordable Act of 2019; HR 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019; HR 1868, the Health Care Affordability Act, to expand subsidies in the ACA individual marketplace HR 1870, the Family Health Care Affordability Act, to fix the family glitch S 1935, the Family Coverage Act, to fix the family glitch Issues related to surprise billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; Issues relating to curbing health care costs; H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act; Issues related to Breast Density and Mammography Reporting; Anti-cancer medication cost-sharing parity respecting H.R. 1409; A national family caregiving strategy respecting S. 1719 and H.R. 1028; Issues relating to FDA regulation of laboratory tests, Verifying Accurate Leading-edge IVCT Development Act of 2018 or the VALID Act of 2018; H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018; H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for; H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials; Additional issues related to reducing disparities in cancer clinical trials; Issues related to improving quality of life for cancer survivorship; H.R. 1948 & S. 518, the Lymphedema Treatment Act H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day H.R. 1730 and S. 741, the Cancer Drug Parity Act; and Cannabis research issues, including S. 2032.

Contacted: White House Office; Health & Human Services, Dept of (HHS); SENATE; Labor, Dept of (DOL); Energy, Dept of; Veterans Affairs, Dept of (VA); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Environmental Protection Agency (EPA); Natl Institutes of Health (NIH); U.S. Agency for International Development (USAID); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS)

Bills named: H.R. 647 (116th), H.R. 3630 (116th), H.R. 4897 (116th), H.R. 986 (116th), S. 2080 (116th), H.R. 1868 (116th), H.R. 1425 (116th), S. 741 (116th), H.Res. 14 (116th), H.R. 1870 (116th), S. 2358 (116th), S. 1107 (116th), H.R. 2222 (116th), S.Res. 223 (116th), H.R. 1884 (116th), H.Res. 282 (116th), S. 2032 (116th), S. 518 (116th), H.R. 1028 (116th), H.R. 1010 (116th), H.R. 1948 (116th), H.R. 1409 (116th), H.R. 1730 (116th), H.R. 987 (116th), H.R. 1966 (116th), H.R. 1386 (116th), S. 1719 (116th)

Medicare/Medicaid MMM

Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including: HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills; HR 3107, Improving Seniors Timely Access to Care Act of 2019, on prior authorization in the Medicare Advantage Program CMS-issued regulations pertaining to Medicare Part B reimbursement; HR 913, The CLINICAL TREATMENT Act, Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trial; Issues related to potential Administration guidance relating to giving states the option to block grant their Medicaid program; Issues related to Puerto Ricos Medicaid program, including H.R. 3631, Territories Health Care Improvement Act. Issues related to utilization management in Medicare Part D plans; issues related to the Medicare Part D caps Potential legislation for lowering prescription drug costs and lowering out of pocket costs for Medicare beneficiaries; and CMS proposed regulatory changes on the six protected classes policy within the Medicare Part D prescription drug benefit.

Contacted: White House Office; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); Energy, Dept of; State, Dept of (DOS); SENATE; Environmental Protection Agency (EPA); Veterans Affairs, Dept of (VA); U.S. Agency for International Development (USAID); Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Labor, Dept of (DOL)

Bills named: S. 668 (116th), H.R. 3107 (116th), H.R. 1570 (116th), H.R. 3631 (116th), H.R. 913 (116th)

Budget/Appropriations BUD

FY 2020 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; funding for development of nuclear isotopes for medical diagnostic technology; and issues related to global health funding for cervical cancer screening & treatment and HPV vaccination.

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —
CAROLINE POWERS —
DENYS C SYMONETTE —

Contacted: Food & Drug Administration (FDA); Veterans Affairs, Dept of (VA); Health & Human Services, Dept of (HHS); Environmental Protection Agency (EPA); White House Office; Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); SENATE; Energy, Dept of; U.S. Agency for International Development (USAID); Labor, Dept of (DOL); Natl Institutes of Health (NIH); State, Dept of (DOS); HOUSE OF REPRESENTATIVES

Tobacco TOB

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including: Implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation; Issues relating to FDA regulation of electronic cigarettes and cigars; S. 655 and H.R.1498, Stopping Appealing Flavors in E-Cigarettes for Kids Act; S. 1048 and H.R. 2111, Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction Act; H.R.1854 & S.9, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 2084, the Stopping Consumption of Tobacco by Teens Act of 2019; H.R. 2339, Reversing the Youth Tobacco Epidemic Act of 2019; S. 1258 and H.R. 2411, Tobacco to 21 Act; Issues related to FDA tobacco control to be considered in House and Senate in the FY20 Agriculture Appropriations legislation and CDC tobacco activities as considered in the Labor, Health and Human Services Appropriations legislation; H.R. 293, Youth Vaping Prevention Act of 2019; S. 616, E-Cigarette youth Protection Act; S. 1253, Preventing Online Sales of E-Cigarettes to Children Act; S. 1541, Tobacco-Free Youth Act; S. 1895, Lower Health Care Costs Act regarding tobacco 21 age of sale provisions; S 1832, Smoke-Free Schools Act; S. 2726, Banning Smoking on Amtrak Act of 2019; and Issues related to smoke-free policies for the Veterans Health Administration, H.R. 3700 and S. 2106.

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —
CAROLINE POWERS —
DENYS C SYMONETTE —

Contacted: Energy, Dept of; White House Office; HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); U.S. Agency for International Development (USAID); State, Dept of (DOS); SENATE; Environmental Protection Agency (EPA); Labor, Dept of (DOL); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Veterans Affairs, Dept of (VA)

Bills named: S. 9 (116th), H.R. 2411 (116th), S. 1258 (116th), S. 616 (116th), S. 2726 (116th), S. 1541 (116th), H.R. 2339 (116th), S. 1048 (116th), H.R. 2084 (116th), S. 2106 (116th), H.R. 293 (116th), H.R. 2111 (116th), S. 1253 (116th), H.R. 1498 (116th), H.R. 1854 (116th), H.R. 3700 (116th), S. 655 (116th), S. 1895 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.